MW 342.4 Da, Purity >98%. Potent, selective PDE3 inhibitor (IC50 values are 27 and 50 nM for PDE3A and PDE3B, respectively). Inhibits ADP-induced platelet aggregation (IC50 = 16.8 μM). Antithrombotic effects in vivo. Orally active.
3' 5' cyclic nucleotide phosphodiesterase, 5''-cyclic nucleotide phosphodiesterase 1A, 5''-cyclic nucleotide phosphodiesterase 1B, 5''-cyclic nucleotide phosphodiesterase 1C, 5''-cyclic phosphodiesterase, 5''-cyclic phosphodiesterase A, 5''-cyclic phosphodiesterase B, 61 kDa Cam-PDE, 63 kDa Cam-PDE, ACLS, AI847709, Adipocyte cAMP phosphodiesterase cGMP inhibited, Atherosclerosis, susceptibility to, included, BXR, CAM-PDE-1A, CGB-PDE, CGI PDE, CGI-PDE A, CGI-PDE B, CGIP1, CGIPDE1, CGMP inhibited cAMP phophodiesterase, CHNG1, CN5A, CN5N, Calcium/Calmodulin stimulated cyclic nucleotide phosphodiesterase, Calcium/calmodulin dependent 3' 5' cyclic nucleotide Phosphodiesterase 1B, Calcium/calmodulin dependent 3' 5' cyclic nucleotide phosphodiesterase 1A, Calcium/calmodulin dependent 3'5' cyclic nucleotide phosphodiesterase 1C, Calcium/calmodulin-dependent 3'', Calmodulin stimulated phosphodiesterase PDE1B1, Calmodulin-dependent Phosphodiesterase, Cam-PDE 1B, Cam-PDE 1C, Cyclic GMP-inhibited phosphodiesterase A, Cyclic GMP-inhibited phosphodiesterase B, Cyclic nucleotide phosphodiesterase, DKFZp686N23123, DNA binding protein, ER, ER-alpha, ER-beta, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen resistance, included, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Glioma associated oncogene family zinc finger 3, HDL cholesterol, augmented response of, to hormone replacement, included, HSPDE1A, HSPDE1C1A, HcGIP1, HcGIP1, rat, homolog of, Human 3'5' cyclic nucleotide Phosphodiesterase, Human cGMP inhibited cAMP phosphodiesterase mRNA, LGR 3, MGC26303, MGC75129, Myocardial infarction, susceptibility to, included, NR1I2_HUMAN, NR3A1, NR3A2, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, ONR 1, OTTHUMP00000004041, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, OTTMUSP00000010350, Oncogene GLI3, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, PAF receptor, PAF-R, PAP A, PAPB, PAR, PAR q, PDE 5, PDE1A_HUMAN, PDE1B1, PDE1B_HUMAN, PDE1C_HUMAN, PDE3A_HUMAN, PDE3B_HUMAN, PDE5A1, PDE5A_HUMAN, PDES 1B, PPD IV, PRR, PTAFR_HUMAN, Phosphodiesterase 1A, Phosphodiesterase 1A calmodulin dependent, Phosphodiesterase 1B, Phosphodiesterase 1B calmodulin dependent, Phosphodiesterase 1C, Phosphodiesterase 1C calmodulin dependent, Phosphodiesterase 1C calmodulin dependent 70kDa, Phosphodiesterase 3A, Phosphodiesterase 3A cGMP inhibited, Phosphodiesterase 3B, Phosphodiesterase 3B cGMP inhibited, Phosphodiesterase 5A, Phosphodiesterase 5A cGMP specific, Phosphodiesterase isozyme 5, Platelet-activating factor receptor, Pregnane X receptor, Presumed 63kDa form of the type 1 cyclic nucleotide phosphodiesterase family known as PDE1B, RNESTROR, RP23-470B20.1, SXR, Seven transmembrane helix receptor, Steroid and xenobiotic receptor, TSH Receptor, TSHR_HUMAN, Thyroid adenoma hyperfunctioning, Thyroid carcinoma with thyrotoxicosis, Thyroid stimulating hormone receptor, isoform 2, Thyroid-stimulating hormone receptor, Thyrotropin receptor, Thyrotropin receptor I, Thyrotropin receptor I, hTSHR I, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Zinc finger protein GLI 3, cAMP Phosphodiesterase, adipocyte, cGMP-inhibited, cAMP phosphodiesterase myocardial cGMP inhibited, cGMP binding cGMP specific 3' 5' cyclic nucleotide phosphodiesterase, cGMP binding cGMP specific 35 cyclic nucleotide phosphodiesterase, cGMP binding/cGMP specific phosphodiesterase, cGMP inhibited 3 5 cyclic phosphodiesterase B, cGMP inhibited 3' 5' cyclic phosphodiesterase A, cGMP specific 3'5' cyclic phosphodiesterase, cGMP specific phosphodiesterase PDE5A2, cGMP specific phosphodiesterase type 5A, cGMP-binding cGMP-specific phosphodiesterase, cGMP-inhibited 3'', cGMP-specific 3'', hCam-1, hCam-3, hTSHR I, pregnane X nuclear receptor variant 2
MW 342.4 Da, Purity >98%. Potent, selective PDE3 inhibitor (IC50 values are 27 and 50 nM for PDE3A and PDE3B, respectively). Inhibits ADP-induced platelet aggregation (IC50 = 16.8 μM). Antithrombotic effects in vivo. Orally active.
Soluble in DMSO to 100 mM.
Potent, selective PDE3 inhibitor (IC50 values are 27 and 50 nM for PDE3A and PDE3B, respectively). Inhibits ADP-induced platelet aggregation (IC50 = 16.8 μM). Antithrombotic effects in vivo. Orally active.
The Estrogen Receptor (ER) and TSH Receptor (TSH-R) are proteins involved in hormone signaling. Estrogen Receptor about 66 kDa is expressed in tissues like breast uterus and ovaries responding to estrogen hormone. TSH Receptor or thyrotropin receptor found in the thyroid gland is critical for thyroid function. Proteins like Gli3 are transcriptional regulators involved in development. Pregnane X Receptor (PXR) is a nuclear receptor that controls expression of genes in liver and intestine. Phosphodiesterase (PDE) family enzymes including PDE1A PDE1B PDE1C PDE3A PDE3B and PDE5A play roles in cyclic nucleotide breakdown affecting cellular signaling. PAF-R or platelet-activating factor receptor is a G-coupled receptor involved in immune responses.
Estrogen Receptor helps regulate gene expression influencing cell proliferation and differentiation often interacting with co-regulators like SRC-1. TSH Receptor enables thyroid hormone production affecting metabolism. Gli3 functions in limb and brain development part of Shh signaling complex. PXR modulates xenobiotic metabolism engaging with CYP3A4 enzyme. PDE enzymes degrade cAMP and cGMP influencing muscle contraction learning and memory. PDE inhibitors have pharmaceutical applications targeting these processes. PAF-R activation leads to inflammation by engaging downstream signaling pathways.
Estrogen Receptor is integral to estrogen signaling and interacts with proteins like HER2 impacting cellular growth pathways. TSH Receptor participates in thyroid hormone synthesis through the cAMP signaling pathway. Gli3 relates to Sonic Hedgehog (Shh) pathway coordinating with proteins such as SUFU. PXR links with xenobiotic metabolism pathways involving enzymes like CYP450. PDEs are in cyclic nucleotide metabolism impacting vasodilation pathways along with proteins like nitric oxide synthase.
Estrogen Receptor involvement is significant in breast cancer where it correlates with HER2. Abnormal TSH Receptor function can cause Graves’ disease an autoimmune disorder affecting the thyroid also linked to autoantibodies against thyroglobulin. Gli3 mutations associate with polydactyly and holoprosencephaly. PXR polymorphisms might influence drug metabolism affecting treatment efficacy. PDE dysfunction impacts cardiovascular diseases and erectile dysfunction where PDE5 inhibitors are therapeutic. PAF-R overactivity connects to asthma and inflammation disorders mediated by cytokines.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com